Biochanin A partially restores the activity of ofloxacin and ciprofloxacin against topoisomerase IV mutation-associated fluoroquinolone-resistant Ureaplasma species

Jin, Hong; Chen, Qi; Zou, Yanping; Kong, Yingying; Ruan, Zhi; Ding, Honghui; Xie, Xinyou; Zhang, Jun

doi:10.1099/jmm.0.000598

Cited by 16 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is active against some Grampositive and many Gram-negative bacteria including bacterial pathogens responsible for community-acquired pneumonias, bronchitis, urinary tract infections, and gastroenteritis [27]. Ciprofloxacin functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, necessary to separate bacterial DNA, thereby inhibiting cell division [28,29]. It has been reported that ciprofloxacin can be used in CSD [8,30].…”

Section: Discussionmentioning

confidence: 99%

Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro

Xiao-yan

Shi

et al. 2020

BMC Microbiol

View full text Add to dashboard Cite

Background: Bartonella henselae is a Gram-negative bacterium transmitted to humans by a scratch from cat in the presence of ectoparasites. Humans infected with B. henselae can result in various clinical diseases including local lymphadenopathy and more serious systemic disease such as persistent bacteremia and endocarditis. The current treatment of persistent B. henselae infections is not very effective and remains a challenge. To find more effective treatments for persistent and biofilm Bartonella infections, in this study, we evaluated a panel of drugs and drug combinations based on the current treatment and also promising hits identified from a recent drug screen against stationary phase and biofilm recovered cells of B. henselae. Results: We evaluated 14 antibiotics and 25 antibiotic combinations for activity against stationary phase B. henselae (all antibiotics were at 5 μg/ml) and found that ciprofloxacin, gentamicin, and nitrofurantoin were the most active agents, while clofazimine and miconazole had poor activity. Drug combinations azithromycin/ciprofloxacin, azithromycin/ methylene blue, rifampin/ciprofloxacin, and rifampin/methylene blue could rapidly kill stationary phase B. henselae with no detectable CFU after 1-day exposure. Methylene blue and rifampin were the most active agents against the biofilm B. henselae after 6 days of drug exposure. Antibiotic combinations (azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, rifampin/methylene blue) completely eradicated the biofilm B. henselae after treatment for 6 days. Conclusions: These findings may facilitate development of more effective treatment of persistent Bartonella infections in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro

Xiao-yan

Shi

et al. 2020

BMC Microbiol

View full text Add to dashboard Cite

show abstract

“…Synergistic antimicrobial activity of biochanin A along with fluoroquinolones was also noticed against antibiotic-resistant Ureaplasmas spp. [124]. Biochanin A was investigated as mycobacterial efflux pump inhibitor (EPI) in Mycobacterium smegmatis.…”

Section: Anti-microbial Activitiesmentioning

confidence: 99%

Biochanin A: A novel bioactive multifunctional compound from nature

Sarfraz

Javeed

Shah

et al. 2020

Science of The Total Environment

118

View full text Add to dashboard Cite

“…BCA synergizes with quinolones to inhibit Staphylococcus aureus by increasing the accumulation of ciprofloxacin and suppressing the bacterial expression of the norA protein and the efflux system [adenosine triphosphate (ATP)-binding ABC transporters] but has no inhibitory effect on the bacteria alone (Liu et al, 2011; Zou et al, 2014). Synergy between quinolones and BCA has also been observed in the treatment of pathogenic mycoplasma and Mycobacterium avium (Jin et al, 2017; Cannalire et al, 2017). The most common mechanism underlying these drug–drug interactions is the inhibition of the CYP system, which is responsible for the metabolism of nearly 90% of drugs in humans.…”

Section: Bca Plays Complex Roles In Paradoxical Drug–drug Interactionsmentioning

confidence: 99%

Perspectives Regarding the Role of Biochanin A in Humans

et al. 2019

View full text Add to dashboard Cite

Biochanin A (BCA) is an isoflavone mainly found in red clover with poor solubility and oral absorption that is known to have various effects, including anti-inflammatory, estrogen-like, and glucose and lipid metabolism modulatory activity, as well as cancer preventive, neuroprotective, and drug interaction effects. BCA is already commercially available and is among the main ingredients in many types of supplements used to alleviate postmenopausal symptoms in women. The activity of BCA has not been adequately evaluated in humans. However, the results of many in vitro and in vivo studies investigating the potential health benefits of BCA are available, and the complex mechanisms by which BCA modulates transcription, apoptosis, metabolism, and immune responses have been revealed. Many efforts have been exerted to improve the poor bioavailability of BCA, and very promising results have been reported. This review focuses on the major effects of BCA and its possible molecular targets, potential uses, and limitations in health maintenance and treatment.

show abstract

Biochanin A partially restores the activity of ofloxacin and ciprofloxacin against topoisomerase IV mutation-associated fluoroquinolone-resistant Ureaplasma species

Cited by 16 publications

References 33 publications

Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro

Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro

Biochanin A: A novel bioactive multifunctional compound from nature

Perspectives Regarding the Role of Biochanin A in Humans

Contact Info

Product

Resources

About